Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions
Recommended Citation
Mansoor T, Ismayl M, Virani SS, Nambi V, Misra A, Jia X, Fudim M, Greene SJ, Sperling L, Parikh S, Rifai MA, Koshy SK, Abramov D, Minhas AMK. Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions. J Clin Lipidol. 2026;20(2):262-269.
Document Type
Article
Publication Date
2-1-2026
Publication Title
J Clin Lipidol
Keywords
Humans, Heart Transplantation, Allografts, Hypolipidemic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors
Abstract
BACKGROUND: Heart transplantation represents an increasingly utilized procedure for end-stage heart failure patients.
CURRENT EVIDENCE: Cardiac allograft vasculopathy (CAV) is a post-transplant complication of pathological vasculature remodeling and remains an important cause for long-term graft failure and mortality. Current preventive strategies for CAV include optimization of vascular risk factors and pharmacotherapy with statins and immunosuppressants.
CONCLUSION: Despite demonstrated post-transplant mortality benefit and reduction in CAV with statins, the role of other pharmacotherapies on CAV reduction through low-density lipoprotein cholesterol (LDL-C) lowering remains less established. This review explores established evidence as well as evolving pathways for LDL-C lowering strategies to prevent CAV.
Medical Subject Headings
Humans; Heart Transplantation; Allografts; Hypolipidemic Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors
PubMed ID
41494936
Volume
20
Issue
2
First Page
262
Last Page
269
